Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LABCORP HOLDINGS INC. Director's Dealing 2018

May 25, 2018

30237_dirs_2018-05-25_55ff2270-b090-45ac-879d-e5420fdfc260.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2018-05-23

Reporting Person: KING DAVID P (Director, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-05-23 Common Stock M 49966 $84.86 Acquired 271635.3298 Direct
2018-05-23 Common Stock S 44566 $175.2738 Disposed 227069.3298 Direct
2018-05-23 Common Stock S 5400 $176.1281 Disposed 221669.3298 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-05-23 Non-qualified Stock Options $84.86 M 49966 Disposed 2022-05-23 Common Stock (49966) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 27811 Indirect
Common Stock 47357 Indirect

Footnotes

F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2: The price of $175.2738 per share represents a weighted average of sales prices ranging from $175.00 to $175.998 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: The price of $176.1281 per share represents a weighted average of sales prices ranging from $176.01 to $176.54 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F4: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F5: The option vested in three equal annual installments beginning on 05/24/2013 and is now fully exercisable.